Frontotemporal Dementia Treatment Drug Market to Showcase Immense Growth During the Study Period (2019–2032) | DelveInsight
The overall frontotemporal dementia market is expected to rise due to increasing prevalence cases over the globe and thus the surge in treatment options. Due to the lack of treatment, the expected launch of emerging therapy for frontotemporal dementia treatment will boost the market in the forecasted period (2023–2032).
New York, USA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- *Frontotemporal Dementia Treatment Drug Market to Showcase Immense Growth During the Study Period (2019–2032) | DelveInsight*
*The overall frontotemporal dementia market is expected to rise due to increasing prevalence cases over the globe and thus the surge in treatment options. Due to the lack of treatment, the expected launch of emerging therapy for frontotemporal dementia treatment will boost the market in the forecasted period (2023–2032).*
DelveInsight’s *Frontotemporal Dementia Market Insights* report includes a comprehensive understanding of current treatment practices, frontotemporal dementia emerging drugs, market share of individual therapies, and current and forecasted frontotemporal dementia market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
*Key Takeaways from the Frontotemporal Dementia Market Report*
· As per DelveInsight’s analysis, the frontotemporal dementia market size was found to be *USD 92 million* in 2021 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
· As per DelveInsight estimates, in the 7MM, total frontotemporal dementia diagnosed prevalent cases in the 7MM were found to be *~128K* in 2021, which might increase by the end of 2032.
· Globally leading frontotemporal dementia companies such as *Alector Inc., Transposon Therapeutics, Inc, Oncolys BioPharma Inc,* *Prevail Therapeutics, Coya Therapeutics, Alector, Inc., Passage Bio, WaVe Life Sciences, Eli Lilly, CAMP4 Therapeutics, SOLA Biosciences, Denali Therapeutics, Neurimmune, Autifony Therapeutics, *and others are developing novel frontotemporal dementia drugs that can be available in the frontotemporal dementia market in the coming years.
· Some of the key therapies for frontotemporal dementia treatment include *Latozinemab (AL001), OBP-601, DNL593, PBFT02, PR006, WVE-004, LY3884963**, *and others.
Discover which therapies are expected to grab the major frontotemporal dementia market share @ *Frontotemporal Dementia Market Report*
*Frontotemporal Dementia Overview*
Frontotemporal disorders, often abbreviated as FTD, represent a cluster of neurocognitive conditions characterized by a progressive decline in executive function, behavior, and language skills. This group includes three main types: behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), and movement disorders. While the precise cause remains unknown in most cases, genetics plays a role in 15-40% of individuals with FTD. Those with a family history of these disorders are at a higher risk of inheriting them. Common FTD symptoms encompass atypical behaviors, emotional disturbances, communication difficulties, work-related challenges, and impaired mobility. FTD often presents a diagnostic challenge due to its clinical symptoms, which can mimic those of various other dementias and psychiatric disorders. On average, it takes approximately 3.6 years from the onset of symptoms to achieve an accurate diagnosis. The diagnostic process for FTD typically involves imaging and the analysis of blood or cerebrospinal fluid.
*Frontotemporal Dementia Epidemiology Segmentation*
The frontotemporal dementia epidemiology section provides insights into the historical and current frontotemporal dementia patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The *frontotemporal dementia market report* proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
· Total FTD Diagnosed Prevalent Cases
· FTD Type-specific Diagnosed Prevalent Cases
· FTD Gene-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving frontotemporal dementia epidemiology trends @ *Frontotemporal Dementia Epidemiological Insights*
*Frontotemporal Dementia Treatment Market *
At present, there are no FDA, EMA, or PMDA-approved therapies designed to modify the course of FTD. Treatment strategies currently rely on the off-label use of medications for symptom management, with limited support from randomized, placebo-controlled clinical trials. FTD exhibits a range of cognitive and behavioral symptoms, and both pharmacological and non-pharmacological interventions can address specific aspects of the disorder. Non-pharmacological interventions are generally the initial approach, with medication considered in conjunction. The FTD drugs market is categorized based on drug classes such as Selective Serotonin Reuptake Inhibitors (e.g., *Citalopram, Fluoxetine*), Antipsychotic Agents, Cholinesterase Inhibitors (e.g., *donepezil, rivastigmine, galantamine*), NMDA Receptor Antagonists (*Memantine*), and *Benzodiazepine *Antianxiety Drugs.
Selective serotonin reuptake inhibitors (SSRIs) and similar medications are considered promising options for patients with frontotemporal dementia (FTD) due to their historical success in alleviating symptoms similar to problematic behaviors seen in psychiatric patients. Commonly prescribed SSRIs and antipsychotics are often used for individuals with behavioral variant FTD (bvFTD). Cholinesterase inhibitors, on the other hand, have shown limited efficacy and may even worsen behavioral or motor symptoms in FTD and progressive supranuclear palsy (PSP) patients.
Furthermore, physical therapy focusing on gait and balance training can play a crucial role in fall prevention and improving overall mortality rates. For individuals with primary progressive aphasias, speech therapy delivered by a specialized therapist experienced in neurodegenerative aphasias can be highly beneficial. Additionally, home safety assessments conducted by occupational therapists can enhance daily living for patients dealing with impaired fine motor skills or apraxia.
Learn more about the FDA-approved drugs for frontotemporal dementia @ *Drugs for* *Frontotemporal Dementia Treatment** *
*Key Frontotemporal Dementia Therapies and Companies*
· Latozinemab (AL001): Alector Inc.
· OBP-601: Transposon Therapeutics, Inc/Oncolys BioPharma Inc
· DNL593: Denali Therapeutics Inc
· PBFT02: Passage Bio, Inc.
· PR006: Prevail Therapeutics
· WVE-004: Wave Life Sciences
· LY3884963: Eli Lilly and Company
To know more about frontotemporal dementia clinical trials, visit @ *Frontotemporal Dementia Treatment Drugs** *
*Frontotemporal Dementia Market Dynamics*
The dynamics of frontotemporal dementia are anticipated to change in the coming years. The *lack of an established drug for FTD* could serve as an advantage for emerging medications, positioning them to dominate the market upon approval. A resurgence in *FTD research* offers optimism for future progress, with a focus on enhancing diagnostic capabilities and *broadening treatment options* through innovative therapeutic approaches.
Furthermore, many potential therapies are being investigated for the treatment of frontotemporal dementia, and it is safe to predict that the treatment space will significantly impact the frontotemporal dementia market during the forecast period. Moreover, the *anticipated introduction of emerging therapies* with improved efficacy and a further *improvement in the diagnosis rate* are expected to drive the growth of the frontotemporal dementia market in the 7MM.
However, several factors are impeding the growth of the frontotemporal dementia market. FTD often goes undetected and is *frequently misdiagnosed* due to the inherent challenges in making an accurate diagnosis and the overlapping symptoms with other disorders. As the field of *developmental research advances*, several prominent organizations are actively conducting clinical trials for emerging FTD drugs, which may lead to *significant competition* among them.
Moreover, frontotemporal dementia treatment poses a *significant economic burden* and disrupts patients’ overall well-being and QOL. Furthermore, the frontotemporal dementia market growth may be offset by *failures and discontinuation of emerging therapies*, *unaffordable pricing*, *market access and reimbursement issues*, and a *shortage of healthcare specialists*.
*Frontotemporal Dementia Report Metrics* *Details*
Study Period 2019–2032
Frontotemporal Dementia Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Frontotemporal Dementia Market Size in 2021 USD 92 Million
Key Frontotemporal Dementia Companies Alector Inc., Transposon Therapeutics, Inc, Oncolys BioPharma Inc, Prevail Therapeutics, Coya Therapeutics, Alector, Inc., Passage Bio, WaVe Life Sciences, Eli Lilly, CAMP4 Therapeutics, SOLA Biosciences, Denali Therapeutics, Neurimmune, Autifony Therapeutics, and others
Key Frontotemporal Dementia Therapies Latozinemab (AL001), OBP-601, DNL593, PBFT02, PR006, WVE-004, LY3884963, and others
*Scope of the **Frontotemporal Dementia** Market Report*
· *Therapeutic Assessment: *Frontotemporal Dementia current marketed and emerging therapies
· *Frontotemporal Dementia* *Market Dynamics:* Attribute Analysis of Emerging Frontotemporal Dementia Drugs
· *Competitive Intelligence Analysis:* SWOT analysis and Market entry strategies
· *Unmet Needs, KOL’s views, Analyst’s views, Frontotemporal Dementia Market Access and Reimbursement*
Discover more about frontotemporal dementia drugs in development @ *Frontotemporal Dementia Clinical Trials*
*Table of Contents*
1. Frontotemporal Dementia Market Key Insights
2. Frontotemporal Dementia Market Report Introduction
3. Frontotemporal Dementia Market Overview at a Glance
4. Frontotemporal Dementia Market Executive Summary
5. Disease Background and Overview
6. Frontotemporal Dementia Treatment and Management
7. Frontotemporal Dementia Epidemiology and Patient Population
8. Patient Journey
9. Frontotemporal Dementia Marketed Drugs
10. Frontotemporal Dementia Emerging Drugs
11. Seven Major Frontotemporal Dementia Market Analysis
12. Frontotemporal Dementia Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
*Related Reports*
*Frontotemporal Dementia Epidemiology Forecast*
*Frontotemporal Dementia Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted frontotemporal dementia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
*Frontotemporal Dementia Pipeline*
*Frontotemporal Dementia Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key frontotemporal dementia companies, including *Prevail Therapeutics, Coya Therapeutics, Alector, Inc., Passage Bio, WaVe life Sciences, CAMP4 Therapeutics, SOLA Biosciences, Denali Therapeutics, Neurimmune, Autifony Therapeutics, *among others.
*Dementia with Lewy Bodies Pipeline*
*Dementia with Lewy Bodies Pipeline Insight – 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dementia with Lewy bodies companies, including *Eli Lilly and Company, CuraSen Therapeutics, Inc., Athira Pharma, Aptinyx Inc., *among others.
*Parkinson’s Disease Market*
*Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast – 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease companies, including *Cerevel Therapeutics, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceuticals, BioVie, Cerevance, Clene Nanomedicine, Intra-Cellular Therapies, Hoffmann-La Roche, Prothena Corp,* among others.
*Alzheimer's Disease Market*
*Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2032 *report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer’s disease companies including *Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd., Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., *among others.
*Psychosis in Parkinson’s and Alzheimer’s Disease Market*
*Psychosis in Parkinson’s and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast – 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson’s and Alzheimer’s disease companies, including *Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme,* among others.
*Other Trending Reports*
*Digestive System Fistula Market** | **Dementia With Diabetes Market** | **Leber's Hereditary Optic Neuropathy Market** | **Pecoma Market** | **Adamantinoma Market** | **Pegfilgrastim Biosimilar Insight** | **Functional Constipation Market** | **DDR Defective Tumors Market** | **Nephrotic Syndrome Pipeline** | **Pelizaeus-Merzbacher Disease Market** | **Hepatic Impairment Market** | **Primary Ciliary Dyskinesia Market** | **Surgical Bleeding Market** | Radiotherapy-Induced** Oral Mucositis Market** | **Relapsed Chronic Lymphocytic Leukemia CLL Market** | **Galactosemia Market** | **Glabellar Lines Market** | **Homozygous Familial Hypercholesterolemia Market** | **HR Positive/ HER2 Negative Breast Cancer Market** | **Lebers Hereditary Optic Neuropathy LHON Market** | **Nonalcoholic Fatty Liver Disease NAFLD Market** | **Orthotic Devices Market** | **Polypoidal Choroidal Vasculopathy Market** | **Sporadic Inclusion Body Myositis Market** | **Acid Sphingomyelinase Deficiency ASMD Market** | **B-Cell Chronic Lymphocytic Leukemia Market** | **Coccidioidomycosis Market** | **Frontotemporal Dementia Pipeline** | **Granulomatosis With Polyangiitis Market** | **Malignant Pleural Mesothelioma Market** | **Nocturnal Enuresis Market** | **Postmyocardial Infarction Syndrome Market** | **Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market** | **Typhoid Fever Market** | **Ventricular Dysfunction Market** | **Burkitt Lymphoma Market** | **Chronic Progressive Multiple Sclerosis Market** | **Emesis Market** | **Fenebrutinib Market** | **Gastric Neuroendocrine Tumors Market** | **Juvenile Rheumatoid Arthritis Market** | **Persistent Epithelial Defects Market** | **Post-Polycythemia Vera Myelofibrosis Market** | **Primary Mediastinal Large B-Cell Lymphoma Market** | **Spinocerebellar Ataxias Market** | **Systemic Inflammatory Response Syndrome Market** | **Triple Negative Breast Cancer Market** | **Visceral Pain Associated With GI Disorders Market** | **Adrenal Cortex Neoplasms Market** | **Adrenal Insufficiency Market** | **Artificial Lung Devices Market** | **Atopic Keratoconjunctivitis AKC Market** | **Autonomic Dysfunction Market** | **Bradycardia Treatment Devices Market** | **Bullous Pemphigoid Market** | **Cone Rod Dystrophy Market** | **Cutaneous Lupus Erythematosus Market** | **Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market** | **Dermal Regeneration Matrix Market** | **Heart Pump Devices Market** | **Hemiplegia Market** | **Hepatic Impairement Market** | **Immunologic Deficiency Syndrome Market** | **Implantable Infusion Pump Market** | **Menorrhalgia Market Size** | **Myocarditis Market** | **Myopia Treatment Devices Market** | **Ocular Hypertension Market *
*Related Healthcare Services*
*Healthcare Consulting*
*Healthcare Competitive Intelligence Services*
*Healthcare Asset Prioritization Services*
*About DelveInsight*
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve*.*
*Connect with us on* *LinkedIn**|**Facebook**|**Twitter*
CONTACT: Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com